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OBJECTIVES Our aim was to confirm the poor prognosis related to thoracic aortic plaques, in particular
aortic debris, diagnosed by transesophageal echocardiography (TEE) and to evaluate patients’
prognosis as a function of the antithrombotic treatment.
BACKGROUND Aortic atheroma (AA) has been widely studied. However, it is still not known which
antithrombotic treatment should be adopted in this disease.
METHODS Patients referred for TEE and diagnosed with AA were followed. All thromboembolic events
and deaths were recorded during a follow-up of 22 6 10 months. The antithrombotic
treatment to be adopted was left to the discretion of the practitioner in charge of the patient.
RESULTS Aortic atheroma was found in 12% of all TEE performed and in 27.5% of TEE performed
for stroke. This prevalence was higher when no other etiology existed to explain the stroke
(p , 0.001). During follow-up, an end point occurred in 22.5% of patients. The more severe
the AA the greater the incidence of events (p 5 0.007). A higher mortality rate is shown in
patients with aortic debris (p 5 0.049). Compared with those treated with oral anticoagu-
lants, patients with aortic plaques .4 mm thick treated with antiplatelets had more embolic
events and combined events (p 5 0.01 and p 5 0.007, relative risk [RR] 5 5.9, 95%
confidence interval [CI] 5 1.4 to 15, respectively); patients with aortic debris had more
combined events and a higher mortality rate (p 5 0.001, RR 5 7.1, 95% CI 5 1.2 to 19 and
p 5 0.019, RR 5 9.1, 95% CI 5 1.2 to 25, respectively).
CONCLUSIONS We confirm the high incidence of vascular events and deaths in patients with AA. We have
demonstrated, for the first time in this condition, a better outcome among patients treated
with oral anticoagulants versus antiplatelets. (J Am Coll Cardiol 1999;33:1317–22) © 1999
by the American College of Cardiology
Atherosclerotic disease of the thoracic aorta as a cause of
embolic events has been well documented (1–18). However,
although the prevalence of aortic atherosclerosis and its
value as an indicator of poor prognosis have been studied,
the prognostic value of “aortic debris,” a particular form of
aortic atheroma, is less well documented. Furthermore, the
optimal antithrombotic treatment in the presence of such
disease remains unknown.
The first aim of our study was to evaluate the risk of
future vascular events as a function of the antithrombotic
treatment prescribed in patients with aortic atheroma (AA)
diagnosed by transesophageal echocardiography (TEE).
Furthermore, we sought to confirm the poor prognosis
related to AA of the thoracic aorta and, in particular, to
assess the prognosis related to aortic debris.
METHODS
Patients referred to our echocardiographic laboratory for
TEE from January 1993 to December 1995 and presenting
with AA were followed. At the time of inclusion, informa-
tion was recorded relative to arterial hypertension, hyper-
cholesterolemia, smoking, diabetes mellitus, peripheral vas-
cular disease and atrial fibrillation.
The TEE procedure was performed by two practitioners
in awake patients with local premedication (lidocaine spray).
The investigation was performed using a Hewlett-Packard
Sonos 1000 (biplane probe: 5 MHz). The thoracic aorta was
examined with special care in all patients after the usual
examination of the cardiac structures. The location and
thickness of all aortic plaques were carefully noted. All
examinations were recorded on VHS allowing a second
physician, with no knowledge of the patient status, to view
the procedure and make an independent assessment of the
AA classification.
Aortic atheroma was classified using modified FAP study
criteria (14). As one of our aims was to individualize the
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prognosis of patients with aortic debris, we divided the
patients into three groups according to the thickness of the
aortic wall and the presence of an atherosclerotic mobile
component in the lumen of the aorta. As a result, grade I
was defined as a plaque with a thickness ranging from 1 to
3.9 mm. Grade II was defined as a plaque of more than
4 mm in thickness. Grade III defined any plaque, whatever
its thickness, with an obvious mobile component (aortic
debris). As the prognosis of patients presenting with aortic
plaque ,1 mm in thickness has been demonstrated to be no
different from the prognosis of patients with aortic plaques
of 1 to 3.9 mm (14), aortic plaques less than 1 mm thick
were not taken into account.
No interobserver variability was observed concerning the
classification of AA.
Data collection. During follow-up, information was ob-
tained from all patients or their family (when patients were
unable to answer). Forty-five percent of patients were
examined at least once at the end of follow-up. The
remaining 55% were interviewed by telephone. In particular,
we sought to collect all clinical events possibly caused by an
embolic mechanism such as stroke, transient ischemic at-
tack, acute ischemia of a limb and death. Whatever the
event, the latter was always confirmed by the physician in
charge of the patient or from hospital records.
It is noteworthy that, when no other embolic potential
etiology apart from AA was found, patients were referred
back to their physician with no particular recommendation
concerning the treatment to be adopted. The antithrom-
botic treatment followed was divided into two groups: oral
anticoagulants (OAC) and antiplatelet agents (APA) (aspi-
rin or ticlopidine hydrochloride). Neither the data on
anticoagulation intensity (i.e., the International Normalized
Ratio) nor the reasons for the choice of either APA or OAC
(i.e., contraindication to warfarin) were prospectively col-
lected.
Statistical analysis. Data concerning patients’ characteris-
tics are expressed as mean 6 SD. For patient outcome,
comparisons are made using the three-grade classification of
aortic atheroma defined by the echocardiographic criteria
and the antithrombotic treatment followed.
Univariate comparisons of characteristics between pa-
tients were performed with the chi-square test for categorial
variables (gender, history of diabetes, hypertension, current
smoking status, atrial fibrillation) and with two-sample t
tests for continuous variables (age and left ventricular
ejection fraction).
End points were stroke or peripheral embolic event on
the one hand and death, of whatever etiology, on the other.
Kaplan–Meier estimates of the distribution of times from
inclusion to end point were computed. Log rank analysis
was performed to compare the event curves for different
groups. Relative risks (RRs) with 95% confidence interval
(CI) (Taylor method) are given. In all analyses, a p value of
0.05 or less was considered to indicate statistical signifi-
cance. The data were analyzed with SAS (version 6.11).
RESULTS
Patients and prevalence of aortic plaques. During the
study period, 1,116 TEEs were performed and examined by
two independent practitioners. Transesophageal echocardi-
ography was prescribed for the following reasons: to seek an
embolic cause after an embolic event (n 5 429), to check for
valvular disease (n 5 397), to look for clots in the left atrium
before cardioversion (n 5 149), to confirm or rule out
endocarditis or aortic dissection (n 5 86) or for miscella-
neous reasons (n 5 55). Protruding atheroma was found in
139 patients, that is, 12% of all cases. Among these, TEE
was prescribed in 118 cases (85%) for an embolic event
(stroke in 107 cases [77%], an embolic event in a limb in 11
cases [8%]) and for other reasons in 21 cases (15%).
As a result, a significant atheroma, as defined above, was
found in 25.6% of patients referred for TEE after a stroke
(107/418), and in 27.5% of patients referred for TEE after
a stroke or peripheral embolic event (118/429).
It is worth noting that, among the patients referred for an
embolic event, and despite a complete etiologic search
(carotid Doppler, ECG Holter monitoring, transthoracic
and TEE), in all, prevalence of aortic plaques was statisti-
cally more frequent in patients in whom no other etiology
for this embolic event was found, that is, 47.7% of cases
(56/118) versus 16.7% (52/311) in the group of patients in
whom a potential cause of emboli was discovered (p ,
0.0001).
Study group. Ten of the 139 patients were lost during
follow-up. As a result, our study group comprised 129
patients. Mean age was 68 6 8.7 years, 71% were male, 32%
were diabetics, 39% were current smokers and 24% had
Table 1. Aortic Atheroma Classification and Location of Aortic







n 45 50 34 129
Ascending aorta (n) 19 14 13 46 (35.6%)
Descending aorta (n) 22 13 11 46 (35.6%)
Both segments (n) 5 20 12 37 (28.7%)
The total of plaque location is .129 because one patient can present several aortic
plaques.
Abbreviations and Acronyms
AA 5 aortic atheroma
APA 5 antiplatelet agents
CI 5 confidence interval
OAC 5 oral anticoagulants
RR 5 relative risk
TEE 5 transesophageal echocardiography
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arterial hypertension. Their classification according to the
severity of the AA is shown in Table 1. It is worth noting
that 33 of 34 patients presenting with a complex athero-
sclerotic plaque with a mobile component (aortic debris:
grade III) presented with at least one plaque .4 mm in
thickness. Mean follow-up was 22 6 10 months.
In 92 out of the 129 cases (71.3%), aortic plaques
involved a single portion of thoracic aorta: the ascending
aorta and/or aortic arch (to the ostium of the left subclavian
artery) in half the cases, and the descending thoracic aorta in
the other half. In 37 cases (28.7%), aortic plaques were
localized in both aortic segments. This diffused localization
was more frequent in grades II and III (Table 1).
Table 2 shows the treatment followed according to the
aortic atheroma. Fifty-four percent of all patients were
treated with APA (aspirin [250 mg] or ticlopidine
[500 mg]); 46% were treated with OAC. None was treated
with both OAC and APA.
It is worth noting that the great majority (71%) of group
I patients were treated with APA (p , 0.01), whereas the
distribution between the two treatments was identical for
grade II and III patients.
Vascular events and death during follow-up. During
follow-up, 12 thromboembolic events (eight strokes, four
peripheral embolic events) and 17 deaths occurred. All
thromboembolic events were documented by computed
tomography scan (no hemorrhagic stroke occurred) or
angiography. As a result, during follow-up, 22.5% of the
129 patients presented with one of the serious events being
collected; the global mortality rate was 13.2% (Table 3).
Death was related to documented vascular events in five
cases (three acute myocardial infarctions, one type A aortic
dissection, one massive stroke). Sudden death (defined as
witnessed sudden unexpected death within 6 h of the onset
of symptoms from a stable medical condition, or death
occurring ,24 h after an individual had been seen in a stable
condition) occurred in six other patients. Other patients
died of causes having no clear relation to their aortic
atheromas, including cancer (n 5 2), cardiac failure (n 5 2),
pulmonary embolism (n 5 1) and renal failure of unknown
cause (n 5 1).
Mean age of patients who died or who experienced a
vascular event was 69 6 6 years (range 50 to 80) and was not
statistically different from the rest of the study group (p 5
0.16).
Prognostic value of aortic atheroma severity. MORTALITY.
Considering deaths from any cause, mortality rate was 4%,
14% and 23.5% respectively, for grades I, II and III.
When comparing the three groups, although the thresh-
old of statistical significance is not reached, log rank analysis
shows a trend in favor of higher mortality in patients with
more severe AA (p 5 0.069). Comparison between two
groups (grade II vs. I, grade III vs. I and grade III vs. II)
shows a gradual increase in mortality risk (Table 3).
However, if one compares more severely diseased patients
(grade III) with the others (grades I and II), a statistically
higher mortality rate is observed in the grade of more
severely diseased patients (nine deaths out of 95 patients in
grades I and II vs. eight deaths out of 34 patients in grade
III) (log rank 5 3.82, RR 5 2.51, 95% CI 5 1.7 to 10)
(Table 3).
EMBOLIC EVENTS. Of grade I, 4.4%, 10% of grade II and
14.7% of grade III patients suffered a documented embolic
event (stroke for two grade I patients, three grade II patients
and three grade III patients; a peripheral embolic event for
two grade II patients and two grade III patients). The
occurrence of an embolic event in the three groups, al-
though showing a trend, is not statistically different (p 5
0.26). However, although not statistically significant, com-
parisons between two groups show a gradual increase for
embolic event risk (Table 3).
COMBINED END POINTS. The occurrence of combined
events (embolic event or death) increased with the severity
of the disease. The more severe the AA, the worse the
patients’ prognosis. In effect, when comparisons are made
between the three grades, Kaplan–Meir curves show a
significant difference with a higher incidence of events in
the more severe grades (p 5 0.007) (Fig. 1).






Grade I (n 5 45) 32 (71%) 13 (29%) ,0.01
Grade II (n 5 50) 23 (46%) 27 (54%) NS
Grade III (n 5 34) 15 (44%) 19 (56%) NS
Total (n 5 129) 70 (54%) 59 (46%) NS









RR III vs. I
[95% CI]
RR III vs. II
[95% CI]
RR II vs. I
[95% CI]
Stroke or PEE (n) 2 (4.4%) 5 (10%) 5 (14.7) 0.26 3.3 [0.68–16] 1.47 [0.4–4.7] 2.25 [0.46–11]
Death (n) 2 (4.4%) 7 (14%) 8 (23.5)† 0.069 5.3 [1.2–23] 1.7 [0.7–4.2] 3.15 [0.7–14]
Combined end point (n) 4 (8.8%) 12 (24%) 13 (39.2)‡ 0.007 4.3 [1.55–12] 1.59 [0.83–3] 2.7 [0.94–7.8]
*p values (log rank test) are given for comparison between the three groups. †p 5 0.049 for grade III vs. grades I 1 II. ‡p 5 0.03 for grade III vs. grades I 1 II.
CI 5 confidence interval; PEE 5 peripheral embolic event; RR 5 relative risk.
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TREATMENT EFFICACY. If one analyzes the occurrence of
embolic events alone, there is no difference between grade I
patients whatever the treatment used. In grade III a trend is
shown for fewer embolic events in patients treated with
OAC (p 5 0.08). However, in grade II a real benefit is
highlighted with OAC. Indeed, the risk of an embolic event
is higher, in this group, when patients are not treated with
OAC (p 5 0.01) (Table 4).
As regards the mortality rate, although no statistical
difference exists concerning mortality in grade I or II patients
according to the treatment, a significant benefit is observed in
group III patients taking OAC as compared with those
patients of the same grade classification taking APA (p 5
0.019, RR 5 9.1, 95% CI 5 1.2 to 50) (Table 4) (Fig. 2).
As a result, although in grade I patients the incidence of
combined end points is not different according to the
treatment used (p 5 0.7), the occurrence of these combined
end points is significantly lowered in patients treated with
OAC versus those treated with APA in grade II and III
patients (p 5 0.007, RR 5 5.9, 95% CI 5 1.4 to 15; and
p 5 0.001, RR 5 7.1, 95% CI 5 1.2 to 19, respectively)
(Table 4) (Fig. 3 and 4).
DISCUSSION
Prevalence and prognosis value of aortic atheroma.
Among the 1,112 TEEs performed, we found a 12%
prevalence of AA. This prevalence rose to 27.5% when
considering TEE performed to look for an emboligenic
source.
These figures are very similar to those reported in
published reports (5,7,10). In our study, the great majority
of patients in whom AA was found were checked for an
embolic event (108/129: 84%). It is worth noting that when
an AA is found, the result of an etiologic search to find a
cause for the embolic event is more frequently unproductive
(p , 0.001). This supports a possible causal link between
AA and embolic events.
We confirm the poor prognosis of patients with AA, in
particular those with plaques greater than 4 mm in thick-
ness. The high incidence of vascular events or death over a
period of almost two years is consistent with previous data
(5,7,8,14). Our result means that one patient out of four
presenting with an aortic plaque .4 mm and more than one
patient out of three with aortic debris will experience a
vascular event or die within two years.
One of our major findings is that, during follow-up,
vascular events or deaths increased proportionately to the
severity of AA. The more severe the AA, the more frequent
the vascular events (p 5 0.007). In particular, when com-
pared with patients with aortic plaques ,4 mm thick with
no mobile component (grade I), patients with aortic debris
had a higher risk for combined events and death (RR 5 4.3,
95% CI 5 1.5 to 12; and RR 5 5.3, 95% CI 5 1.2 to 23,
respectively).
Figure 1. Kaplan–Meier curves showing the event-free survival
rate according to the aortic atheroma severity.
Table 4. Comparison of Events According to Aortic Atheroma and Antithrombotic Treatment
OAC APA p Value* RR [95% CI]
Grade I
Stroke or embolic events 0/13 1/32 0.26 NA
Mortality rate 1/13 1/32 0.50 1 [0.1–5.8]
Combined end points 1/13 2/32 0.7 1.21 [0.1–11]
Grade II
Stroke or embolic events 0/27 5/23 0.01 NA
Mortality rate 2/27 5/23 0.14 2.9 [0.6–14]
Combined end points 2/27 10/23 0.007 5.9 [1.4–15]
Grade III
Stroke or embolic events 1/19 4/15 0.08 5 [0.6–50]
Mortality rate 1/19 7/15 0.019 9.1 [1.2–50]
Combined end points 2/19 11/15 0.001 7.1 [1.2–19]
*p value by log rank test. APA 5 antiplatelet agents; CI 5 confidence interval; NA 5 RR calculation not applicable; OAC 5
oral anticoagulants; RR 5 relative risk.
Figure 2. Kaplan–Meier curves showing the mortality rate in
grade III patients according to the antithrombotic treatment.
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The same analysis tends to show a worse prognosis for
these patients as compared with those with AA plaques
.4 mm thick (but no aortic debris), a condition already
associated with a poor prognosis.
Finally, mortality rate alone is higher when patients with
aortic debris are compared with those with significant AA
but no aortic debris (grade I1II) (p 5 0.049, RR 5 2.51,
95% CI 5 1.7 to 10).
These aortic debris were first described by Karalis et al.
(5). They have been associated with an increased incidence
of embolization but, to our knowledge, not with a higher
mortality (5,7,11,16,17).
Many published data support the hypothesis that com-
plex aortic plaques are valuable “markers” of severe and
widespread atheroma. In particular, the link between AA
diagnosed with TEE and coronary artery disease has been
demonstrated (19,20). We believe this may explain why
severe AA, though not always the direct cause of death, is
correlated with higher global mortality.
Benefit of oral anticoagulants. The other major result in
our study is the benefit of oral anticoagulation as opposed to
antiplatelet agents. We demonstrate this benefit for embolic
events and combined end points in patients with aortic
plaques .4 mm thick, and for combined end points and also
mortality in patients with aortic debris.
In particular, our results show that patients with aortic
debris treated with APA have a nine-fold higher mortality
risk as compared with the same patients treated with OAC.
On the other hand, patients with aortic plaque .4 mm
thick have almost a six-fold higher risk for combined events
when treated with APA as compared with OAC.
In a recent study, dealing with 31 patients followed for
about 10 months, Dressler et al. reported a lower incidence
of vascular events in those patients treated with warfarin as
compared with those treated with antiplatelets (21). In the
FAP study (14), among patients with plaques .4 mm thick,
no significant difference in the event rate between patients
receiving warfarin and those receiving aspirin was noted.
However, only nine patients (20%) received warfarin in this
group. Furthermore, patients with a mobile lesion received
warfarin for one to three months and aspirin thereafter. We
believe this may have minimized efficacy of OAC.
In our study population, the incidence of aortic debris,
which obviously represents the most severe form of AA, was
frequent, involving 26% of patients. This may have in-
creased the incidence of vascular events or deaths and
probably made it easier to demonstrate the beneficial effect
of OAC.
The main limitation of our study could be that treatment
was not randomly assigned. Fortunately, however, the
distribution of the two antithrombotic regimens was homo-
geneous in the most severe groups (Table 2).
Furthermore, in clinical practice, physicians usually use
oral anticoagulation instead of antiplatelet agents only when
the “global vascular risk” is higher. Indeed, Table 5 details a
comparison between the main patient characteristics in the
two treatment groups and shows that patients treated with
OAC more frequently presented with atrial fibrillation or
left ventricular dysfunction. This may have minimized the
beneficial effects of OAC we found.
We did not use a control group without atherosclerotic
disease of the aorta. As a result, the comparisons shown
were made between three severe forms of AA. However,
some published data suggest that a patient with aortic
plaque between 1 and 3.9 mm in thickness (our grade I)
runs the same risk as a patient with no aortic plaque (14).
Many treatments may have a favorable effect on AA (e.g.,
hypocholesterolemic drugs, antithrombotics). In addition to
a comparison of medical and surgical strategies, further
studies are needed to investigate these medications that may
have a favorable impact on this condition. In particular,
randomized studies are warranted. These should compare
Figure 3. Kaplan–Meier curves showing the event-free survival in
grade II patients according to the antithrombotic treatment.
Figure 4. Kaplan–Meier curves showing the event-free survival
rate in grade III patients according to the antithrombotic treat-
ment.
Table 5. Comparison of the Main Characteristics of the Two




(n 5 70) p
Age (yr) 68.8 6 9 67.5 6 7 NS
Gender (% male) 71 69 NS
Hypertension (%) 38 34 NS
Diabetes mellitus (%) 32 29 NS
Smoking (%) 49 46 NS
Atrial fibrillation (%) 12 1.4 ,0.05
Ejection fraction (%) 46 55 ,0.05
AOC 5 oral anticoagulants; APA 5 antiplatelet agents (aspirin or ticlopidine).
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not only different antithrombotic treatments but also inves-
tigate the need for such a treatment (placebo).
Recent studies have emphasized the possible changes in
the echocardiographic appearance of aortic debris and even
the poor correlation between echocardiographic data and
pathologic findings (22,23). They suggest that what is
described as aortic debris may often constitute a superim-
posed thrombus on a classic aortic plaque. Whatever the
pathologic findings, the link between “aortic debris” and
poorer prognosis signifies at very least that these ulcerated
aortic plaques present a greater propensity to evolve with all
inherent complications. Moreover, the favorable evolution
(decrease in size) of these aortic debris described by serial
TEE examinations in patients treated with OAC is an
argument for OAC treatment (22).
Conclusions. We confirm that patients with protruding
AA seen by TEE are at high risk for the development of
vascular events, especially embolic events and death. In
particular, the presence of aortic debris is correlated with a
higher mortality rate whatever the cause.
Furthermore, we demonstrated, for the first time, a better
outcome among patients treated with OAC compared with
those treated with antiplatelet agents. This beneficial effect
is highlighted in patients with aortic plaques .4 mm in
thickness for embolic events alone or combined embolic
events and mortality. The same benefit is observed in
patients with aortic debris for combined embolic events and
mortality but also mortality alone. This finding should
justify further randomized studies.
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